The frequent co-occurrence of hypertension and type 2 diabetes mellitus is well recognised, and the prevalence of hypertension in subjects with type 2 diabetes is almost twice that of the non-diabetic population. 1 Hypertension not only exacerbates the already high risk of widespread atherosclerotic vascular disease in diabetic subjects, but also increases the risk of microvascular complications. 2 In diabetic subjects, systolic hypertension is well established as a risk factor for cardiovascular disease. 2, 3 The United Kingdom Prospective Diabetes Study (UKPDS) has recently demonstrated a 15% increase in coronary artery disease per 10 mm Hg rise in systolic blood pressure. 4 The beneficial effects of antihypertensive therapy in non-diabetic populations is now well established. The Systolic Hypertension in the Elderly Program (SHEP) study showed that over 5 years treatment, reduction of systolic blood pressure with a thiazide, beta-blocking drug or reserpine, from a mean of 155 mm Hg to 143 mm Hg reduced major cardiovascular events by 55 events per 1000 patients treated. 5 The recently reported Systolic Hypertension in Europe (Syst-Eur) trial has further confirmed this finding using the calcium antagonist, nitrendipine. 6 A total of 4695 patients were randomly assigned to nitrendipine with the possible addition of enalapril and hydrochlorothiazide or matching placebo. At 2 years, systolic blood pressure fell by 10.1 mm Hg more in the active treatment group compared to the placebo group, and fatal or non-fatal cardiovascular end-points fell by 53 per 1000 per 5 years treatment, an overall reduction of 31%.
Until recently, the assumption had been that these beneficial effects could be extrapolated to the dia-betic population. There was, however, no evidence that the use of antihypertensive therapy in this population did attenuate the risk of microvascular or macrovascular complications in type 2 diabetes. Indeed, much of the evidence for reduction of microvascular disease has been extrapolated from work done in type 1 diabetes. There were also concerns that certain classes of antihypertensive agents could adversely affect outcome in patients with type 2 diabetes due to worsening of other metabolic abnormalities, in particular dyslipidaemia. Furthermore, the threshold level at which to treat hypertension in diabetes had not been established. This article reviews the recent large, prospective studies which have attempted to address these issues in hypertensive patients with type 2 diabetes.
Does antihypertensive therapy reduce mortality and morbidity in type 2 diabetes?
Analysis of the subgroup of diabetic subjects who formed part of the SHEP study has been reported. 7 A total of 583 elderly (mean age 70 years) diabetic subjects were studied, and treatment with chlorthalidone with or without atenolol or reserpine was compared to placebo. Tight blood pressure control achieved a systolic blood pressure of 9.8/2.2 mm Hg less than the less tight blood pressure control group. Relative risk of myocardial infarction was 0.46 (95% confidence intervals (CI) 0.24 -0.88) These findings have been confirmed and extended by the recently reported UKPDS 8 and Hypertension Optimal Treatment (HOT) study (see later). 9 The UKPDS set out to determine whether tight glycaemic control could reduce adverse complications in subjects with type 2 diabetes. In a factorial design, embedded within the original UKPDS cohort, a multicentre, randomised controlled trial of tight (blood pressure Ͻ150/85 mm Hg) versus less tight (blood pressure Ͻ180/105 mm Hg) blood pressure control was undertaken. The less tight control group (n = 390) were treated with antihypertensive drugs, avoiding angiotensin-converting enzyme (ACE) inhibitors or beta-blockers. The tight control group were further randomised to either captopril (n = 400) or atenolol (n = 358), and other drugs were added if control was inadequate, the suggested sequence being frusemide, nifedipine, methyldopa and prazosin. Median follow-up was 8.4 years and mean blood pressure in the tight control group was 10/5 mm Hg lower than the less tight control group (144/82 mm Hg vs 154/87 mm Hg). After 9 years follow-up, a 32% reduction in diabetes related deaths, a 44% reduction in strokes and a 34% reduction in combined macrovascular end-points was seen. Although a 21% reduction in myocardial infarction was observed, this did not reach statistical significance. The numbers needed to treat to prevent one diabetes related death was 15. The results thus provide firm evidence that tight blood pressure control is beneficial in patients with type 2 diabetes. Of note was the fact that after 9 years follow-up, 29% of patients were on three or more antihypertensive therapies to lower blood pressure. Examination of the cost effectiveness of tight blood pressure control in hypertensive patients with type 2 diabetes has shown an incremental cost of £720 per life year gained, indicating a very good value. 10 Interestingly, the UKPDS demonstrated that the benefit of reducing blood pressure in patients with type 2 diabetes is much greater than the benefit of improving glycaemic control, which appeared to influence microvascular complications far more than macrovascular ones.
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Subgroup analysis of the 492 diabetic patients in the Syst-Eur Trial has been published recently. 12 This showed that treatment of systolic hypertension in elderly diabetic subjects was beneficial compared to placebo in reducing total mortality (55% reduction), cardiovascular mortality (76% reduction), cardiovascular end-points (69% reduction), strokes (73% reduction) and all cardiac events (63% reduction). Percentage reduction in end-points was much greater in the diabetic subjects treated with calcium antagonist therapy compared to non-diabetic subjects, such that the excess risk of cardiovascular disease due to diabetes was almost abolished.
There is therefore conclusive evidence that reduction in blood pressure in hypertensive diabetic subjects is beneficial in improving life expectancy and reducing macrovascular complications.
Does treatment of hypertension reduce microvascular complications in type 2 diabetes?
This important question has also been addressed in the UKPDS. 8 Retinopathy was defined as the presence of one microaneurysm in one eye or worse using retinal photography, with progression defined as a two-step change in modified Early Treatment of Diabetic Retinopathy Study (ETRDS) grade. Visual acuity was assessed with the ETRDS chart, with deterioration in vision defined as a reduction in three lines. Albuminuria was assessed using spot clinic urine albumin concentrations, with microalbuminuria defined as a concentration у50 mg/l and macroalbuminuria defined as у300 mg/l. Development of neuropathy was assessed using loss of both ankle or both knee reflexes or mean biothesiometer reading from both toes 25V or greater.
Overall, the tight blood pressure control group had a 37% reduction in microvascular disease compared to the less tight control group. The effect seen was predominantly due to reduction in development or progression of retinopathy. The tight control group had a 34% reduction in risk of retinal photocoagulation, and a 47% lower in risk of reduction in visual acuity. In contrast, there was no significant reduction in risk of microalbuminuria or macroalbuminuria over 9 years follow-up between the tight and less tight blood pressure control group. There was however, a trend for lower rates of clinical proteinuria in patients treated with captopril (5%) compared to those on atenolol (10%), (P = 0.09). There was also no significant difference in development of neuropathy in the tight versus less tight blood pressure control groups.
The possible methodological problems in assessment of nephropathy status are a major problem in interpretation of the UKPDS. A single spot clinic urine albumin is notoriously difficult to reproduce, having a coefficient of variation of around 60%, and hence appears to have poor sensitivity for the presence of micro-or macroalbuminuria. 13 A further concern is that, in contrast to type 1 diabetes, the predictive value of microalbuminuria for progression to nephropathy in type 2 diabetes is poor. 14 Thus, the question of whether tight blood pressure control prevents the onset of nephropathy in type 2 diabetes has not been answered by the UKPDS. It has been suggested ACE inhibition may reduce microalbuminuria to a greater extent compared to calcium channel blockers. 15 The UKPDS, however, has shown equivalent reductions in microvascular end-points with the use of ACE inhibitor and betablocking agents.
What is the threshold for treatment and target blood pressure for diabetic patients with hypertension?
The threshold for treatment of hypertension in diabetic subjects and the target blood pressure needed to achieve lowest cardiovascular mortality has not previously been ascertained. Concern has been expressed that excessive lowering of blood pressure may lead to an increase in cardiovascular mortality rather than a reduction-the so-called J-shaped curve. 16, 17 The recently published results from the Hypertension Optimal Treatment (HOT) study has shed some light on this. 9 The study was based on the hypothesis that hypertensive patients on treatment still have a higher cardiovascular morbidity and mortality compared to matched normotensive patients, 18 and this difference is likely to be due to inadequate antihypertensive therapy. Some surveys suggest that less than a third of patients on antihypertensive therapy have their blood pressure reduced to below 140/90 mm Hg. 19, 20 The HOT study enrolled nearly 19 000 hypertensive patients (including 1501 diabetic patients), (diastolic blood pressure 100-115 mm Hg) and randomised them to target diastolic blood pressures of р90 mm Hg, р85 mm Hg or р80 mm Hg. In addition, half the subjects in each arm were randomised to receive aspirin. Treatment was commenced with felodipine-a longacting calcium antagonist, and the addition of ACE inhibitors, beta-blockers or diuretics was allowed in order to achieve the target blood pressure. Blood pressure reduction in excess of 20 mm Hg was achieved in the great majority of the patients. The lowest incidence of major cardiovascular events occurred at a mean systolic blood pressure of 138.5 mm Hg and diastolic blood pressure of 82.6 mm Hg, and lowest cardiovascular mortality was seen at a mean systolic blood pressure of 138.8 mm Hg and diastolic blood pressure of 86.5 mm Hg. Further reduction in blood pressure below these levels was not associated with increased benefit, but also was not associated with increased mortality. The HOT study has been criticised for a number of shortcomings. The small difference in achieved blood pressure, (4 mm Hg rather than the planned 10 mm Hg), made significant differences in event rates difficult to ascertain between the groups. There was also criticism of stopping the trial earlier than planned, and hence not achieving the required numbers of events. 21 Furthermore, intention-to-treat analysis appears to show little difference between the three target groups in mortality or cardiovascular events. 22 In contrast, however, the large sub-group of diabetic subjects in the HOT study were analysed on an intention-to-treat basis, and showed highly significant results. In the group randomised to р80 mm Hg (equating to a mean systolic pressure of 139.7 mm Hg and a mean diastolic pressure of 81.1 mm Hg), the number of cardiovascular events was half of that observed in the group randomised to р90 mm Hg (equating to a mean systolic pressure of 143.7 mm Hg and a mean diastolic blood pressure of 85.2 mm Hg). Cardiovascular mortality and total mortality were also significantly reduced in the lowest blood pressure group. Addition of aspirin to the antihypertensive therapy further reduced cardiovascular events by 15%, but at the expense of greater non-fatal bleeding events. No significant effect was seen, however, on cardiovascular mortality in the aspirin treated group.
The findings of the HOT study are supported by the UKPDS, which has shown added benefit in intensifying blood pressure control in diabetic subjects. 8 Achieving a blood pressure of 144/82 mm Hg or less reduced diabetes related deaths, strokes, heart failure and microvascular end-points considerably. These studies therefore suggest a target blood pressure of 140 mm Hg systolic and 80 mm Hg diastolic or less.
The British Hypertension Society (BHS) guidelines on antihypertensive therapy published in 1993 suggested initiation of antihypertensive treatment in patients with a diastolic blood pressure of Ͼ100 mm Hg or between 90 and 99 mm Hg if there was evidence of target organ damage, or a systolic blood pressure Ͼ160 mm Hg in the elderly. 23 Target blood pressure was defined as a diastolic blood pressure Ͻ90 mm Hg, but no firm recommendation was made for systolic blood pressure. These guidelines have generally been extrapolated to diabetic patients.
With the advent of the most recent studies, two new sets of guidelines have been recently published including diabetic patients, both of which take into account the concept of Coronary Heart Disease Risk, based on the Framingham Equation. 24 It is now suggested that decisions on treatment of cardiovascular risk factors, including hypertension should be based on risk of coronary heart disease rather than simply blood pressure alone. The Joint British Recommendations on prevention of coronary heart disease in clinical practice have recently suggested a threshold for treatment as 140/90 mm Hg if coronary risk is greater than 1.5% per year, and a target of 130/80 mm Hg in diabetic subjects. 25 The World Health Organisation/International Society of Hypertension guidelines suggest that patients with diabetes should be stratified into a high risk category, and thus a threshold and target for therapy should again be 140/90 mm Hg, although it is suggested that subjects with evidence of renal disease should have treatment considered at an even earlier stage (130/85 mm Hg). 26 The British Hypertension Society are currently revising their guidelines in the light of the recent evidence, and are likely to suggest a threshold blood pressure for treatment of hypertension as у140/90 mm Hg in anyone with cardiovascular disease, hypertension induced cardiovascular damage, diabetes or micro-and macroalbuminuria. In the absence of these, estimation of coronary heart disease risk using the Framingham equation of over 2% per year should prompt treatment at у140/90 mm Hg. Target blood pressure is likely to be р140/80 mm Hg. Recently, risk stratification charts for diabetic patients incorporating age, sex, smoking status, cholesterol/HDL cholesterol ratio, systolic blood pressure and presence of microalbuminuria have been published, and may be particularly helpful in making decisions on therapy in patients with type 2 diabetes. 27 If a coronary risk of 2% per year was taken as the threshold for therapy, the numbers needed to treat to prevent one coronary event over 10 years would be 20.
Which antihypertensive drugs should be used in diabetic subjects?
Early trials of antihypertensive therapy in hypertensive subjects have commonly used thiazide diuretics, beta-blocking agents and other older drugs as first or second line therapy. It has been suggested that these agents may be disadvantageous in diabetic subjects with hypertension due to the increased risk of deterioration in other metabolic factors. [28] [29] [30] Newer agents such as ACE inhibitors and calcium channel blockers appear to be metabolically neutral and hence may, therefore, offer greater benefit. The efficacy of these two groups of agents has now been extensively studied in a number of recent trials.
Recent reports of serious adverse effects from calcium channel blockers on mortality and morbidity in non-diabetic subjects has caused considerable concern. This is on the basis of retrospective analysis of trial data, where it has been postulated that calcium antagonist drugs may have adverse effects which include higher incidence of cancer, 31 gastrointestinal haemorrhage, 32 perioperative haemorrhage 33 and suicide. 34 Furthermore, a higher incidence of coronary artery disease in subjects treated with calcium antagonists, particularly shortacting calcium antagonists, has been suggested. 35 Until the presentation of the Syst-Eur findings in diabetic patients, the hypothesis that calcium channel blockade may increase cardiovascular mortality was supported by three large studies involving diabetic patients. The Appropriate Blood Pressure Control in Diabetes (ABCD) trial was designed to test the primary hypothesis that intensive blood pressure compared to moderate blood pressure control would prevent or slow the progression of microvascular and macrovascular events. 36 The study was designed to see whether a long-acting dihydropyridine calcium channel blocker (nisoldipine) was equivalent in effect to an ACE inhibitor (enalapril).
The former part of the study, namely intensive (target diastolic blood pressure Ͻ75 mm Hg) versus moderate (target diastolic blood pressure 80-89 mm Hg) blood pressure control has yet to be reported. However, in the hypertensive (baseline diastolic blood pressure Ͼ90 mm Hg) cohort, interim analysis on the 470 patients who were randomised equally to nisoldipine and enalapril has been reported. The study was discontinued early due to a significantly higher incidence of fatal or non-fatal myocardial infarction in the nisoldipine treated group (total of 25 events) compared to the enalapril treated group (total of five events) (risk ratio 9.5 [95% CI 2.3-21.4]). This result was observed despite the enalapril treated group having significantly lower HDL cholesterol levels and higher prevalence of abnormal ankle-brachial index (hence a poorer cardiovascular risk profile) compared to the nisoldipine treated group.
The explanation for this result is unclear. The investigators acknowledge that the difference in rates of myocardial infarction between the groups may be due to the ACE inhibitor being particularly beneficial, and not the calcium antagonist being harmful. It is also of note that a higher proportion of ACE inhibitor treated patients were on additional beta-blocking drugs compared to the calcium antagonist treated patients, which could have added to the cardioprotection. The premature termination of the study has subsequently been criticised by a number of authorities, in particular due to the small number of events on which this decision was based, and the possibility that this the observations were due to chance. 37 Shortly after the ABCD study was reported, similar results were observed in the Fosinopril versus Amlodipine Cardiovascular Events Randomised Trial (FACET). 38 A total of 380 hypertensive (systolic blood pressure Ͼ140 mm Hg or diastolic blood pressure Ͼ90 mm Hg) diabetic subjects were randomised to ACE inhibitor (fosinopril) or calcium antagonist (amlodipine) and followed up for 3.5 years. The patients receiving fosinopril had a lower risk of combined outcome of myocardial infarction, stroke or hospitalised angina than those receiving amlodipine (risk ratio 0.49 [95% CI 0.26-0.95]). The FACET study has also received considerable criticism in that its findings have been based on a small number of events. 37 Furthermore, 56.9% of patients in the study required both the calcium antagonist and ACE inhibitor to control blood pressure, and less events were seen in the dual therapy treated patients, suggesting that this combination of treatments is appropriate in diabetic patients. 39 A third study showing similar findings to the ABCD and FACET studies is the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). 40 This compared the effect of a calcium antagonist (isradipine) with a diuretic (hydrochlorothiazide) on intimal-medial thickness in carotid arteries of 883 patients. A significantly greater number of cardiovascular events was seen in the isradipine treated group compared to the diuretic treated group over 3 years follow-up (5.65% vs 3.17%). This increased risk of cardiovascular events was only significantly higher in hypertensive patients with diabetes or impaired glucose tolerance who received the calcium channel blocker. 41 Of note, however, is the fact that this observation is only based on a total of 21 events over 3 years.
In marked contrast to the findings in these three trials, analysis of a diabetic subgroup of the Syst-Eur trial has found a large reduction in cardiovascular deaths in the calcium antagonist treated group compared to placebo. 12 Further evidence that calcium antagonist therapy is not harmful in diabetic subjects is given by the results of the HOT study 9 (see earlier). These two studies thus provide considerable reassurance for clinicians caring for diabetic subjects. Whilst it seems likely that ACE inhibitor drugs may be more beneficial than calcium antagonists, there is little doubt that the latter drugs are also protective against cardiovascular disease in diabetic subjects with systolic hypertension.
The UKPDS study of hypertension in diabetes has not only examined the effect of tight versus less tight blood pressure control on cardiovascular disease, but also compared the use of ACE inhibitor drugs with beta-blocking agents. 42 Of the 758 patients allocated to tight blood pressure control, 400 were allocated to captopril, and 358 to atenolol. Both drugs were effective in reducing blood pressure to a mean of 144/83 and 141/81 mm Hg respectively. Although this difference in blood pressure was not statistically significant, it is possible the difference may be clinically significant, in view of previous studies showing differences in diastolic blood pressure of 5-6 mm Hg. Both drugs were equally effective in reducing cardiovascular end-points. It should be noted, however, that many more patients on atenolol stopped the therapy before the end of the study (35% in atenolol group, 22% in captopril group) due to side effects compared to those on captopril.
More recently, results of the Captopril Prevention Project (CAPPP) study have been published. 43 This study randomised 10 985 patients with diastolic hypertension (blood pressure Ͼ100 mm Hg) to receive either captopril (± loop diuretic or calcium antagonist) or conventional therapy (either ␤-blockers or thiazides, ± calcium antagonist), with the aim to reduce diastolic blood pressure to less than 90 mm Hg. Overall, no significant difference between conventional and captopril treated groups was seen in the composite primary end-point (fatal and nonfatal myocardial infarction, stroke or other cardiovascular deaths). In the diabetic subgroup, however, (captopril treated, n = 309, conventional treated, n = 263), a significant reduction in myocardial infarction (risk ratio 0.34, [95% CI 0.17-0.67], P = 0.002) and cardiac events (risk ratio 0.67, [95% CI 0.46-0.96], P = 0.030) was seen.
The explanation for the difference in results of the UKPDS and CAPPP studies is unclear, and has not been readily explained by the CAPPP investigators. No data on blood pressure control, and adjunctive therapy in the two groups in the CAPPP study is provided. Despite this, the risk of stroke was in fact higher in the captopril treated group, possibly due to the dose of captopril being given once daily. It is therefore unlikely that better blood pressure control was achieved in the captopril treated group. 44 The power of the CAPPP study may be insufficient to make valid conclusions on the relatively small number of diabetic patients in the study.
Questions not answered by the recent studies
Whilst the recent studies do not fully clarify the role of newer antihypertensive agents in mortality reduction in type 2 diabetes, they do suggest that newer drugs, such as ACE inhibitors and calcium antagonists are safe and effective in patients with type 2 diabetes. A number of questions, however, remain unanswered. The place of the newer antihypertensive agents such as angiotensin-II receptor antagonists in diabetic patients is as yet unclear. The drugs appear to have a good efficacy and side effect profile, and are metabolically neutral. They have theoretical benefits in patients with nephropathy. 45 Alpha-blockers also appear to be metabolically neutral, and may be of benefit in diabetic subjects. Their role in diabetic subjects may be elucidated by the ongoing Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (see later).
A further question is the role of antihypertensive therapy in the treatment of diabetic renal disease. Although antihypertensive therapy is known to reduce the progression of renal disease in established nephropathy in type 2 diabetes, 46 there remains some controversy as to whether ACE inhibitors are superior to other drugs in this context. ACE inhibitors appear to reduce albumin excretion more than other agents, but their effect on glomerular filtration rate appears to be similar. 47 Although hypertensive microalbuminuric type 2 diabetic patients should be treated according to standard criteria to reduce their risk of cardiovascular disease, there is no firm evidence to suggest that antihypertensive treatment of normotensive microalbuminuric individuals with type 2 diabetes reduces progression to renal failure or cardiovascular disease. There is, however, some evidence to suggest that intensified multifactorial intervention in microalbuminuric type 2 diabetic patients can reduce the progression to overt nephropathy. In the Steno type 2 study, 48 conventional treatment was compared to intensified treatment. The group having intensified treatment had antihypertensive therapy aimed for systolic blood pressure Ͻ140 mm Hg and diastolic blood pressure Ͻ85 mm Hg, glycaemic control aimed at a HbA1c Ͻ6.5%, lipid-lowering treatment aiming for total cholesterol Ͻ5.0 mmol/l, triglycerides Ͻ1.7 and HDL cholesterol Ͼ1.7 mmol/l, treatment with ACE inhibitors irrespective of blood pressure and treatment with aspirin irrespective of presence of vascular disease. In the 159 patients randomised and followed up over 3.8 years, the intensive treated group had significantly less progression to macroalbuminuria (odds ratio 0. Table 2 summarises some of the conclusions drawn and questions remaining from the recent clinical trials in hypertensive patients with diabetes. In such patients, the presence of hypertension confers a dramatically increased risk of microvascular and macrovascular disease. Although studies in non-diabetic populations have shown considerable benefit from antihypertensive therapy in terms of reduction of cardiovascular disease, the evidence that this beneficial effect also applies to diabetic subjects, has been lacking. Subgroup analysis of diabetic patients within these large studies has been reassuring. These have shown even greater benefit in lowering blood pressure in diabetic subjects compared to non-diabetic subjects. The threshold level of blood pressure treatment appears to be lower than the 160/95 mm Hg previously suggested. Recent data support a level of 140/90 mm Hg as a threshold for treatment in most type 2 diabetic subjects, and a target level below 140/80 mm Hg should be achieved.
Implications for clinical practice
It is clear that achievement of adequate antihypertensive effects is unlikely with monotherapy. The UKPDS and HOT studies have shown that around one-third of patients required three or more agents to reduce blood pressure adequately. The HOT study demonstrated that the use of a stepwise introduction of antihypertensive therapy could achieve a target blood pressure in over 90% of patients. An issue not addressed in any of these studies is nonpharmacological methods of blood pressure reduction. These include reduction in obesity, regular exercise and reduction in salt intake, all of which can achieve a genuine reduction in blood pressure and a reduction in cardiovascular risk. 49 This modality of treatment remains an important adjunct to drug therapy.
The controversy regarding the choice of antihypertensive therapy in diabetic subjects has been somewhat lessened by the findings of the Syst-Eur and HOT studies, which show major benefit in treating hypertensive type 2 diabetic patients with Table 2 Conclusions and questions Conclusions drawn from the recent trials of hypertension in diabetes ¼ Treating hypertension reduces mortality in patients with diabetes, and the effect is much greater than that seen in non-diabetic patients. ¼ Treating hypertension reduces retinopathy and loss of visual acuity in patients with diabetes.
¼ Treating hypertension is more cost-effective than improving glycaemic control in patients with diabetes.
¼ The threshold for treatment of blood pressure in patients with diabetes is у140/90 mm Hg. ¼ Calcium antagonists and thiazide diuretics are effective in reducing mortality and morbidity in hypertensive patients with diabetes.
¼ ACE inhibitors and beta-blockers are safe and equally effective in patients with diabetes and probably reduce mortality and morbidity. ¼ Most patients with hypertension and diabetes require more than one antihypertensive agent to control blood pressure.
Questions not yet answered by the recent studies calcium antagonists, refuting the findings of smaller and less well designed studies such as the ABCD, FACET and MIDAS. The results of the UKPDS may also give a new lease of life to beta-blocking agents in hypertensive diabetic subjects. The Joint National Committee sixth report on the treatment of hypertension (JNC-VI) suggest that beta-blockers and diuretics should remain first-line therapy for hypertension. 50 Newer guidelines, however, also suggest that calcium antagonists and ACE inhibitors are likely to be equally as effective as first-line agents.
Clearer evidence with regard to the choice of antihypertensive therapy in diabetic subjects may have to await the findings of a number of studies, including the ALLHAT undertaken by the National Heart, Lung and Blood Institute. 51 So far 40 000 patients have been randomised, of whom around 14 000 have diabetes. These patients are being randomised to a calcium channel blocker (amlodipine), ACE inhibitor (lisinopril), alpha-blocker (doxazosin), and a thiazide diuretic (chlorthalidone) to compare effects on fatal or non-fatal coronary heart disease in high risk patients with hypertension older than 55 years. The trial is regularly reviewed by the Data and Safety Monitoring Committee, the last review being in late 1997, and early termination of the study has not occurred due to excess events in the calcium channel blocker group. This provides further reassurance that calcium channel blockers are unlikely to be causing harm in treated subjects. The AngloScandinavian Cardiac Outcomes Trial (ASCOT), is a further large randomised study that will compare combinations of ACE inhibitor plus calcium antagonist versus beta-blocker plus thiazide, in around 18 000 patients, many of whom have diabetes.
Studies are also required to evaluate the newer agents such as angiotensin II antagonists to determine their place in the treatment of hypertension in diabetic subjects. Other large ongoing randomised trials involving diabetic patients are shown in Table 3 .
With the advent of randomised controlled trials examining large numbers of hypertensive patients with type 2 diabetes indicating an undoubted benefit in treating diabetic patients with hypertension, the evidence base is now available to encourage all clinicians to make a significant impact on cardiovascular mortality. Furthermore, cost-benefit analysis indicates that this form of preventative therapy is highly cost-effective. If the conclusions of the present studies are applied to all diabetic patients, many more people with diabetes and hypertension will be alive and enjoying a better quality of life in the future.
